A
Armando Santoro
Researcher at Humanitas University
Publications - 961
Citations - 56759
Armando Santoro is an academic researcher from Humanitas University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 93, co-authored 847 publications receiving 48505 citations. Previous affiliations of Armando Santoro include Aix-Marseille University & University of Milan.
Papers
More filters
Journal ArticleDOI
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
Vivien H.C. Bramwell,Henning T. Mouridsen,Armando Santoro,G. R. P. Blackledge,Riet Somers,D. Thomas,Richard Sylvester,Allan T. van Oosterom +7 more
TL;DR: A higher response rate with less myelosuppression suggests that IFOS may have advantages over CYCLO in combination with such active agents as adriamycin.
Journal ArticleDOI
Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group.
R. Somers,Armando Santoro,Jaap Verweij,P. Lucas,J. Rouëssé,T. Kok,A. Casali,C. Seynaeve,D. Thomas +8 more
TL;DR: The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small cell lung cancer and a comparison between ABC and unlabelled antibody (PAP) procedures is compared.
Journal ArticleDOI
Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy
S. Viviani,E. Negretti,Attilio Orazi,Gabriella Sozzi,Armando Santoro,P. Lissoni,G. Esposti,F. Fraschini +7 more
TL;DR: Preliminary results seem to suggest that melatonin may have a role in the treatment of MDS induced by previous cancer chemotherapy, and no effect was seen on hemoglobin concentration.
Journal ArticleDOI
Outcome of T1N0M0 breast cancer in relation to St. Gallen risk assignment criteria for adjuvant therapy.
I. Garassino,Giuseppe Gullo,Sergio Orefice,Luca Tondulli,Giovanna Masci,Piermario Salvini,M. Eboli,L. Di Tommaso,Laura Giordano,Marco Alloisio,Massimo Roncalli,Armando Santoro +11 more
TL;DR: The very low rate of distant recurrences even in patients with unfavorable prognostic factors seems to support the use of adjuvant systemic therapies but better prognostic and predictive factors are strongly needed for this subset of patients.